assessing the emergence of resistance the absence of biological cost in vivo may compromise fosfomycin treatments for p. aeruginosa infections成本评估耐药性的出现缺乏生物体内可能会影响磷霉素治疗铜绿假单胞菌感染.pdf

Assessing the Emergence of Resistance: The Absence of Biological Cost In Vivo May Compromise Fosfomycin Treatments for P. aeruginosa Infections ´ 1 ´ ´ 2 1 ´ 3 ˜ Alexandro Rodrıguez-Rojas *, Marıa D. Macia , Alejandro Couce , Cristina Gomez , Alfredo Castaneda- ´ 1 2 ´ ´ 1 Garcıa , Antonio Oliver , Jesus Blazquez * ´ ´ ´ ´ 1 Centro Nacional de Biotecnologıa (CNB), Consejo Superior de Investigaciones Cientıficas (CSIC), Madrid, Spain, 2 Servicio de Microbiologıa and Unidad de Investigacion, ´ ´ ´ Hospital Son Dureta, Instituto Universitario de Investigacion en Ciencias de la Salud (IUNICS), Palma de Mallorca, Spain, 3 Servicio de Anatomıa Patologica, Hospital Son Dureta, Palma de Mallorca, Spain Abstract Background: Fosfomycin is a cell wall inhibitor used efficiently to treat uncomplicated urinary tract and gastrointestinal infections. A very convenient feature of fosfomycin, among others, is that although the expected frequency of resistant mutants is high, the biological cost associated with mutation impedes an effective growth rate, and bacteria cannot offset the obstacles posed by host defenses or compete with sensitive bacteria. Due to the current scarcity of new antibiotics, fosfomycin has been proposed as an alternative treatment for other infections caused by a wide variety of bacteria, particularly Pseudomonas aeruginosa. However, whether fosfomycin resistanc